Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

GEORGIA: Hepatitis C Rages in Georgia


AzerNews (07.24.2013): By Sabina Idayatova Aids Weekly Plus

The Georgian Public Broadcaster reported that the Republic of Georgia had the highest hepatitis C virus (HCV) prevalence (200,000 cases) of all countries in the South Caucasus region, with an annual incidence of 2,000 new infections. Mortality rates also were high, as Georgia had no state program for HCV prevention, detection, and treatment, and only 10 percent of Georgia’s population could afford treatment costs. Georgian physicians asserted that these estimates—based on 2004 data—could underestimate actual HCV prevalence and incidence. A report by Azadeh Momenghalibaf, joint program officer for the International Harm Reduction Development and Access to Essential Medicines Initiative, stated that most of the estimated 185 million HCV-infected people in the world lived in low- or middle-income countries with little access to treatment or government response. Momenghalibaf attributed the lack of access and government response to the nature of HCV infections, which could have no symptoms for many years, creating a “hidden epidemic.” According to Momenghalibaf, a 48-week course of HCV treatment with Pegylated-Interferon cost approximately $18,000. Georgian Health Minister David Sergeenko asserted that the country’s entire health budget would not be sufficient to treat all Georgians infected with HCV. Sergeenko estimated that 1,000 HCV-infected Georgians also needed liver transplants, which would have to be carried out abroad. Georgian civil society and patient groups were pressuring Pegylated-Interferon manufacturers Roche and Merck to cut prices; the Georgia government was negotiating for a price that would allow for universal coverage. Georgia has received some international support for HCV healthcare, but this assistance usually applied to patients coinfected with HIV.


Copyright © 2013 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in July 24, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.